Circulating Tumor DNA Methylation Is a Biomarker of Poor Recurrence-free Survival in Locally-Advanced Rectal Cancer.

IF 1.7 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2025-04-01 DOI:10.21873/anticanres.17537

Kiichi Sugimoto, Takahiro Irie, Hirotaka Momose, Saki Kochi, Miyuki Toake, Yuki Tsuchiya, Ryoichi Tsukamoto, Kumpei Honjo, Shun Ishiyama, Makoto Takahashi, Robert M Hoffman, Kazuhiro Sakamoto

{"title":"Circulating Tumor DNA Methylation Is a Biomarker of Poor Recurrence-free Survival in Locally-Advanced Rectal Cancer.","authors":"Kiichi Sugimoto, Takahiro Irie, Hirotaka Momose, Saki Kochi, Miyuki Toake, Yuki Tsuchiya, Ryoichi Tsukamoto, Kumpei Honjo, Shun Ishiyama, Makoto Takahashi, Robert M Hoffman, Kazuhiro Sakamoto","doi":"10.21873/anticanres.17537","DOIUrl":null,"url":null,"abstract":"Background/aim: The aim of this study was to investigate locus-specific circulating-tumor DNA (ctDNA) methylation for predicting long-term outcomes of locally-advanced rectal cancer (LARC) after resection.Materials and methods: In the present study, there were 50 patients without preoperative treatment and 35 patients with preoperative treatment. Methylation analyses for checkpoint with forkhead and ring finger domains (CHFR), sex-determining region Y-box transcription factor 11 (SOX11) and cysteine dioxygenase type 1 (CDO1) used DNA extracted from plasma ctDNA at the time of resection of the primary tumor with curative-intent surgery.Results: Highly-methylated SOX11 in ctDNA was found to be a biomarker of reduced recurrence-free survival (RFS) in LARC. In multivariate analysis, highly methylated SOX11 was an independent prognostic factor for reduced RFS in the group without preoperative treatment.Conclusion: The present study demonstrates that elevated ctDNA methylation of the SOX11 gene is a biomarker for reduced RFS after curative-intent resection of LARC. Patients with high ctDNA methylation of the SOX11 gene may not be optimal candidates for LARC resection. A prospective study is necessary to further validate SOX11 ctDNA methylation as a biomarker for RFS of patients with LARC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1559-1573"},"PeriodicalIF":1.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17537","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The aim of this study was to investigate locus-specific circulating-tumor DNA (ctDNA) methylation for predicting long-term outcomes of locally-advanced rectal cancer (LARC) after resection.

Materials and methods: In the present study, there were 50 patients without preoperative treatment and 35 patients with preoperative treatment. Methylation analyses for checkpoint with forkhead and ring finger domains (CHFR), sex-determining region Y-box transcription factor 11 (SOX11) and cysteine dioxygenase type 1 (CDO1) used DNA extracted from plasma ctDNA at the time of resection of the primary tumor with curative-intent surgery.

Results: Highly-methylated SOX11 in ctDNA was found to be a biomarker of reduced recurrence-free survival (RFS) in LARC. In multivariate analysis, highly methylated SOX11 was an independent prognostic factor for reduced RFS in the group without preoperative treatment.

Conclusion: The present study demonstrates that elevated ctDNA methylation of the SOX11 gene is a biomarker for reduced RFS after curative-intent resection of LARC. Patients with high ctDNA methylation of the SOX11 gene may not be optimal candidates for LARC resection. A prospective study is necessary to further validate SOX11 ctDNA methylation as a biomarker for RFS of patients with LARC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

循环肿瘤DNA甲基化是局部晚期直肠癌无复发生存不良的生物标志物。

背景/目的：本研究的目的是研究位点特异性循环肿瘤DNA （ctDNA）甲基化，以预测局部晚期直肠癌（LARC）切除术后的长期预后。材料与方法：本研究术前未治疗患者50例，术前治疗患者35例。甲基化分析的检查点与叉头和环指结构域（CHFR），性别决定区Y-box转录因子11 （SOX11）和半胱氨酸双加氧酶1型（CDO1）使用的DNA是从原发肿瘤切除时提取的血浆ctDNA进行治疗目的手术。结果：ctDNA中高度甲基化的SOX11被发现是LARC无复发生存期（RFS）降低的生物标志物。在多变量分析中，高度甲基化的SOX11是术前未治疗组RFS降低的独立预后因素。结论：本研究表明，SOX11基因的ctDNA甲基化升高是LARC术后RFS降低的生物标志物。SOX11基因ctDNA高甲基化的患者可能不是LARC切除术的最佳人选。需要一项前瞻性研究来进一步验证SOX11 ctDNA甲基化作为LARC患者RFS的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.